Mode
Text Size
Log in / Sign up

Generalized pustular psoriasis

Part of Psoriasis

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Generalized pustular psoriasis

7 trials tracked for Generalized pustular psoriasis: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 33 citations.

7Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 3 Phase 2 3
  1. Phase 4 A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Completed · 33 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP Completed · 1 cited
  3. Phase 3 An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options Completed
  4. Phase 3 An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options Completed
  5. Phase 2 Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis Completed
  6. Phase 2 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis Completed
Show 1 more trials
  1. Phase 2 A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Generalized pustular psoriasis: what the trials found

New clinical evidence indicates that Imsidolimab (750 mg) is associated with specific rates of skin clearance in patients with generalized pustular psoriasis, with 8% and 2% achieving GPPPGA scores of 0 or 1 across different study arms 1.

Spesolimab has demonstrated significant efficacy in managing GPP. Clinical data shows a statistically significant reduction in the occurrence of at least one GPP flare up to week 48 (p=0.0013) and an improved time to first worsening of the Psoriasis Symptom Scale (p=0.0134) 5. Furthermore, spesolimab was associated with a significantly higher proportion of patients achieving a GPPPGA pustulation subscore of 0 at week 1 (p=0.0004) and a GPPPGA score of 0 or 1 at week 1 (p=0.0118), as well as a higher proportion of patients achieving GPPASI 75 at week 4 (p=0.0081) 7.

Ixekizumab was evaluated in a maintenance dosing period where results showed limited data on specific improvements; however, some participants achieved a Global Improvement Score (GIS) of 2 or improved by at least one point between weeks 12 and 20 2.

Recent results — preliminary, needs further review

  • Imsidolimab showed clinical response rates of 75.0% on the CGI scale and significant reductions in body surface area of erythema with pustules (up to -97.78%) and mJDA-SI total skin lesions scores (up to -62.20%) at week 16, though these findings are not yet corroborated 6.

For the clinician treating this condition

  • Spesolimab significantly reduces the frequency of GPP flares and delays the worsening of psoriasis symptoms over a 48-week period 5.
  • Spesolimab demonstrates rapid early results, with significant improvements in pustule resolution (GPPPGA subscore) and overall severity scores (GPPPGA and GPPASI) by week 1 and week 4 respectively 7.
  • Imsidolimab is associated with measurable rates of near-complete or complete clearance as measured by GPPPGA and PRS scales 1.

AI synthesis of 5 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Psoriasis

Related studies from across the Psoriasis family.

Neural interactions and cellular components in psoriasis may offer new therapeutic targets for treatment
Dermatology Sys. Review
Neural interactions and cellular components in psoriasis may offer new therapeutic targets for treatment New Research Identifies Nervous System Links in Psoriasis Treatment
This systematic review examines the interactions between multiple cellular components and the nervous system in psoriasis. The review aims t…
New research explores how the nervous system interacts with skin cells in psoriasis to help identify new ways to treat the condition.
Ustekinumab May Improve Inverse Psoriasis in Single Case Report
Dermatology Guideline
Ustekinumab May Improve Inverse Psoriasis in Single Case Report Ustekinumab Shows Promise for Treatment of Inverse Psoriasis
This is a single case report of a 32-year-old male with inverse psoriasis treated with four subcutaneous ustekinumab injections. Skin lesion…
A new case report shows how a specific medication, ustekinumab, significantly improved skin lesions and itching for a patient with inverse p…
Guselkumab achieves 88.8% IGA 0/1 at week 16 in Chinese patients with plaque psoriasis
Dermatology RCT
Guselkumab achieves 88.8% IGA 0/1 at week 16 in Chinese patients with plaque psoriasis Trial shows guselkumab helps Chinese patients with plaque psoriasis
This Phase 4 randomized controlled trial of 327 Chinese patients with moderate-to-severe plaque psoriasis found guselkumab significantly sup…
A new trial shows that guselkumab significantly improves skin clarity for Chinese patients living with moderate to severe plaque psoriasis.
Vunakizumab may induce severe ulcerative colitis and hepatic enzyme elevation in patients with psoriatic arthritis
Allergy & Immunology Sys. Review
Vunakizumab may induce severe ulcerative colitis and hepatic enzyme elevation in patients with psoriatic arthritis Vunakizumab Linked to Severe Ulcerative Colitis in Single Case
This case report and literature review describes a single case of severe ulcerative colitis and hepatic enzyme elevation following vunakizum…
A single case report shows a patient developed severe ulcerative colitis and high liver enzymes after receiving vunakizumab injections.
BAT2306 shows comparable efficacy and safety to secukinumab in moderate-to-severe plaque psoriasis
Dermatology RCT
BAT2306 shows comparable efficacy and safety to secukinumab in moderate-to-severe plaque psoriasis Trial shows BAT2306 performs similarly to secukinumab for plaque psoriasis
This Phase 3 randomized controlled trial evaluated 502 adults with moderate-to-severe plaque-type psoriasis. The study found that BAT2306 de…
A new clinical trial shows that the medication BAT2306 offers similar results and safety for plaque psoriasis compared to the established dr…
Older age, higher BMI, and comorbidities are associated with lower clearance rates in psoriasis patients
Dermatology Meta-analysis
Older age, higher BMI, and comorbidities are associated with lower clearance rates in psoriasis patients Factors Like Age and BMI Impact Psoriasis Treatment Success
This meta-analysis of 13,902 patients evaluates predictors of clinical response to biologic therapies in psoriasis. The analysis identifies …
New data shows that age, body mass index, and other health factors can influence how well patients with psoriasis respond to biologic therap…
IL-17 axis targeting shows substantial efficacy but faces cost and delivery hurdles
Drug Pipeline Sys. Review
IL-17 axis targeting shows substantial efficacy but faces cost and delivery hurdles IL-17 blockers show promise for autoimmune diseases
This systematic review examines IL-17 axis targeting with monoclonal antibodies and small-molecule inhibitors across psoriasis, lupus, perio…
New review finds IL-17-targeting drugs work well for psoriasis and other conditions, but cost and side effects remain hurdles.
78 plasma proteins linked to psoriasis; 12 prioritized as potential drug targets
Genetics & Precision Medicine Meta-analysis
78 plasma proteins linked to psoriasis; 12 prioritized as potential drug targets 78 proteins linked to psoriasis may reveal new drug targets
This meta-analysis of genome-wide association studies (GWAS) identified 78 circulating proteins with genetically predicted associations with…
A large genetic study found 78 proteins tied to psoriasis, including 12 promising drug targets. This could lead to new treatments.
Psoriasis patients with moderate to severe disease show higher prevalence of type 2 diabetes
Rheumatology Sys. Review
Psoriasis patients with moderate to severe disease show higher prevalence of type 2 diabetes Psoriasis patients face higher risk of type 2 diabetes
This narrative review explores the link between psoriasis and type 2 diabetes mellitus, highlighting shared inflammatory pathways and metabo…
People with psoriasis are more likely to develop type 2 diabetes because both conditions share common pathways of chronic inflammation.
Chronic dermatologic conditions significantly impact psychological distress and health-related quality of life in pediatric patients
Pediatrics Meta-analysis
Chronic dermatologic conditions significantly impact psychological distress and health-related quality of life in pediatric patients Chronic skin conditions cause significant emotional distress in children
This systematic review of 41 studies examines the impact of chronic skin disorders on psychological outcomes and health-related quality of l…
Children with chronic skin conditions like psoriasis and eczema face high rates of anxiety, depression, and social struggles.
GDF15 acts as a multi-node signaling hub in inflammatory skin diseases and systemic sclerosis
Neurology Sys. Review
GDF15 acts as a multi-node signaling hub in inflammatory skin diseases and systemic sclerosis Growth Factor GDF15 Linked to Skin Aging and Inflammation
This narrative review explores GDF15 as a signaling hub affecting melanocyte activity, fibroblast collagen synthesis, and the IL-23/Th17 axi…
A protein called GDF15 may play a key role in skin aging, pigmentation, and inflammatory conditions like psoriasis.
Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis
Oncology Meta-analysis
Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis New data ranks different treatments for moderate to severe psoriasis
This systematic review and network meta-analysis of 27 RCTs evaluated IL-23/IL-17 inhibitors for moderate-to-severe plaque psoriasis. Guselk…
Comparing several types of biologics helps patients with plaque psoriasis find which medications rank highest for clearing skin and improvin…